FibroTest's Effectiveness in Diagnosing Liver Fibrosis
Author Information
Author(s): Poynard Thierry, Morra Rachel, Halfon Philippe, Castera Laurent, Ratziu Vlad, Imbert-Bismut Françoise, Naveau Sylvie, Thabut Dominique, Lebrec Didier, Zoulim Fabien, Bourliere Marc, Cacoub Patrice, Messous Djamila, Munteanu Mona, de Ledinghen Victor
Primary Institution: Service d'Hépato-Gastroentérologie, Groupe Hospitalier Pitié-Salpêtrière, Université Paris VI, CNRS ESA 8067 Paris, France
Hypothesis
The FibroTest diagnostic value is similar across different chronic liver diseases and fibrosis stages.
Conclusion
FibroTest is an effective alternative to biopsy in patients with chronic hepatitis C and B, ALD, and NAFLD.
Supporting Evidence
- FibroTest was validated in patients with chronic hepatitis C and other liver diseases.
- The mean standardized AUROC for FibroTest was 0.84.
- FibroTest diagnostic value is similar for intermediate and extreme fibrosis stages.
Takeaway
FibroTest is a blood test that helps doctors check for liver damage without needing a painful liver biopsy.
Methodology
Two meta-analyses were performed, one combining published studies and another using an integrated database of individual data.
Potential Biases
Few independent studies in other chronic liver diseases may introduce bias.
Limitations
The number of studies and patients in non-HCV related diseases is smaller than those in HCV.
Participant Demographics
The study included 6,378 subjects with chronic liver diseases: 3,501 HCV, 1,457 HBV, 267 NAFLD, 429 ALD, and 724 mixed.
Statistical Information
P-Value
0.001
Confidence Interval
95% CI, 0.83–0.86
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website